ibrutinib

Dr. Andreas Hausmann und Dr. Richard Schabath im Gespräch mit Prof. Dr. Martin Dreyling, Leiter des Zentrums für maligne Hämatologie, der LMU München Campus Großhadern (CCC München LMU).

Ein Par-Force-Ritt durch die malignen B-Zell Lymphome:

Mantelzellymphom: 

Die Triangle Studie, die Beantragung von Ibrutinib im Alltag, die Bedeutung der autologen Blutstammzelll-Transplantation beim Mantelzellymphom. Welche Therapie ist im Rezidiv indiziert und ändert sich die First Line Therapie evtl. nochmals in der näheren Zukunft?

Follikuläres Lymphom:

Kommt es zur Chemotherapie-freien Firstline Therapie? Gibt es ein Revival für R-Quadrat und wie sind die Schweizer Daten zu interpretieren? Welche Rolle spielt die Hochdosis-Therapie mit autologer Blutstammzelltransplantation derzeit noch? Warum gibt es  Diskrepanzen zwischen der ICC- und der WHO Klassifikation und werden sie noch aufgelöst?

Aggressive Lymphome/ DLBCL:

Wie sollte die Erst-und Zweitlinien Therapie ablaufen? R-CHOP vs Pola-R-CHP? Im Rezidiv ist die Unterscheidung zwischen für CAR T Zell und nicht für CAR T Zell Therapie geeigneten Patientinnen und Patienten entscheidend! 

Welche Therapie kommt in der Drittlinie für welche Patientinnen und Patienten in Frage? 

Welche Entwicklungen wird es in der Zukunft beim DLBCL geben? Welche Sequenz ist die richtige: CAR T Zellen vor oder nach bispezifischen Antikörpern?

Besuchen Sie gerne unsere Website, um mehr zu erfahren. Dort finden Sie weitere Informationen zu unserem Podcast und können vergangene Folgen anhören.

Falls Sie Fragen, Anmerkungen oder Kritik haben, zögern Sie nicht, uns eine E-Mail an info@ng-akademie.de zu senden. Wir freuen uns über Ihr Feedback!

Bleiben Sie mit uns über Instagram verbunden. Folgen Sie uns, um stets auf dem neuesten Stand zu bleiben und keine Updates zu verpassen.

In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of: 

• SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL 
• TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs Chemoimmunotherapy Followed by ASCT in Younger Patients with Previously Untreated MCL 
• ZUMA-2: Brexucabtagene Autoleucel in R/R MCL 
• BRUIN: Pirtobrutinib for Previously Treated MCL 
• GLOW: Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in Previously Untreated CLL 
• FLAIR: Ibrutinib + Venetoclax vs FCR in Previously Untreated CLL 
• ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL 
• ALPINE: Zanubrutinib vs Ibrutinib in Previously Treated CLL 
• BRUIN: Pirtobrutinib for Previously Treated CLL

Presenters: 

Ana Marin-Niebla, MD, PhD
Hematology Consultant, Lymphoma Unit
Vall d’Hebron Institute of Oncology, Hematology Department
Hospital Universitario Vall d’Hebron
Barcelona, Spain

Stephan Stilgenbauer, MD
Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Ulm University
Ulm, Germany

Link to full program: 
https://bit.ly/3MNaUri

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at SOHO 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: 

• Matching-adjusted indirect comparison of 3 randomized phase III trials of ibrutinib for relapsed/refractory CLL 
• Meta-analysis of cardiovascular adverse events with second-generation BTK inhibitors in CLL 
• BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCL
• ViPOR: venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide for relapsed/refractory and treatment-naive MCL

Presenters:

Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California

Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

In this episode, Catherine C. Coombs, MD, and Toby Eyre, MBChB, MD, discuss key trials presented at ICML 2023 evaluating the use of BTK inhibitors in mantle cell lymphoma (MCL). The discussion includes analyses of: 

• Phase II trial of acalabrutinib with rituximab for older patients with untreated MCL 
• BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCL 
• IMCL-2015 GELTAMO: 5-year update ibrutinib for untreated indolent MCL 

Presenters: 

Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California

Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at EHA 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL). The discussion includes analyses of:

• CLL12: final results of the phase III trial of ibrutinib vs placebo in asymptomatic, treatment-naive CLL
• SEQUOIA: extended follow-up of zanubrutinib vs BR in treatment-naive CLL
• CAPTIVATE: 4-year follow-up from the fixed duration cohort of ibrutinib plus venetoclax in CLL/small lymphocytic lymphoma
• Phase II trial of acalabrutinib plus obinutuzumab in treatment-naive CLL
• BRUIN: genomic evaluation of resistance to pirtobrutinib in BTK inhibitor‒pretreated CLL

Presenters:

Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California

Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include:

• Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial today
• Relevance of overall response rate vs progression-free survival for BTK inhibitor therapy
• Approval of ibrutinib/venetoclax combination therapy for patients with CLL
• Key differences between zanubrutinib and acalabrutinib in the treatment of patients with CLL
• How to transition/overlap next therapy in patients with CLL with progression while receiving a BTK inhibitor

Faculty:
Farrukh T. Awan, MD
Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Nicole Lamanna, MD
Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Link to the complete program, including downloadable slidesets and an on-demand webcast:
https://bit.ly/3EjvSKm

In this episode, Christopher R. Flowers, MD, MS, and Kami Maddocks, MD, discuss their choices of recent important trials presented at the Society of Hematologic Oncology 2022 Annual Meeting evaluating the use of BTK inhibitors in chronic lymphocytic leukemia and mantle cell lymphoma. The discussion includes analyses of:

• GLOW: phase III randomized trial of ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab for older or unfit patients with previously untreated chronic lymphocytic leukemia 
• BRUIN: phase I/II study of pirtobrutinib for previously treated mantle cell lymphoma (including previous BTK inhibitor)

Presenters:

Christopher R. Flowers, MD, MS
Department Chair, Department of Lymphoma/Myeloma
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center 
Houston, Texas

Kami Maddocks, MD
Professor of Clinical Internal Medicine
Division of Internal Medicine
Department of Hematology
The Ohio State University
Lymphoma Program Director
The Ohio State University James Cancer Hospital
Columbus, Ohio

In this episode, Julie M. Vose, MD, MBA, and Matthew S. Davids, MD, MMSc, discuss their choices of recent important trials presented at the Pan Pacific Lymphoma Conference 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: 

• BRUIN (CLL/small lymphocytic lymphoma [SLL]): phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)
• SEQUOIA: phase III study evaluating cohort 1 of zanubrutinib vs bendamustine/rituximab in untreated CLL/SLL without del(17p)
• MAJIC: phase III trial in progress of acalabrutinib + venetoclax vs venetoclax + obinutuzumab in previously untreated CLL
• BRUIN (MCL): phase I/II study of pirtobrutinib for previously treated MCL (including previous BTK inhibitor)
• BRUIN MCL-321: phase III trial in progress of pirtobrutinib vs investigator’s choice acalabrutinib, ibrutinib, or zanubrutinib in previously treated, BTK inhibitor–naive MCL
• BRIDGE: series case report from phase II study evaluating zanubrutinib-based induction and maintenance in young patients with MCL

Presenters: 

Julie M. Vose, MD, MBA
Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Link to full program:
https://bit.ly/3OQ6634

In this episode, Othman Al-Sawaf, MD, and Lydia Scarfò, MD, discuss key trials presented at EHA 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: 

• GAIA/CLL13: phase III trial of time-limited venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy as first-line therapy for CLL
• FLAIR: randomized, adaptive-design phase III trial with data reported from ibrutinib + venetoclax and ibrutinib arm; includes measurable residual disease–defined therapy duration
• BRUIN: phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)
• SHINE: phase III study of ibrutinib with bendamustine + rituximab and rituximab maintenance in older patients with MCL

Presenters:

Othman Al-Sawaf, MD
Faculty of Medicine
University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne 
Düsseldorf, Germany
Visiting Scientist
The Francis Crick Institute
UCL Cancer Institute, University College London 
London, United Kingdom

Lydia Scarfò, MD
Laboratory of B-Cell Neoplasia, Division of Experimental Oncology
Strategic Research Program on CLL
Università Vita Salute San Raffaele and IRCCS Ospedale San Raffaele
Milano, Italy

Link to full program:
https://bit.ly/3OQ6634

In this episode, Brad S. Kahl, MD, and Anthony Mato, MD, MSCE, discuss their choices of 3 recent important trials presented at ASCO 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion will include analyses of: 

• The SHINE trial evaluating the addition of ibrutinib to bendamustine/rituximab followed by rituximab maintenance in the first-line setting for older patients with MCL
• 3-year follow-up analysis from the CAPTIVATE fixed-duration cohort of first-line ibrutinib plus venetoclax for CLL/small lymphocytic lymphoma
• Phase I/II study of zilovertamab, an anti-ROR1 antibody, plus ibrutinib in MCL or CLL

Presenters:

Brad S. Kahl, MD
Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri 

Anthony Mato, MD, MSCE
Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

See full program:
https://bit.ly/3OQ6634

In this episode, John M. Burke, MD, a leading expert, and Amy Esposito, FNP-C provide expert insights on key data presented at the 2022 ASCO annual conference for CLL/SLL regarding:

• Updated response and safety results after 3 years of follow-up from the phase II CAPTIVATE study of ibrutinib and venetoclax in patients with previously untreated CLL
• Updated response and remission rates after 4 years of follow-up from a phase II trial of obinutuzumab, ibrutinib, and venetoclax in patients with either treatment-naïve or relapsed/refractory CLL
• Progression free survival and safety results after 5 years of follow-up from the ELEVATE-TN phase III study of Acalabrutinib ± Obinutuzumab vs 
  Obinutuzumab + Chlorambucil as first-line therapy in CLL
• Assessments of whether racial and/or ethnic identity, and socioeconomic status are prognostic factors of survival in CLL

Presenter

John M. Burke, MD
Rocky Mountain Cancer Centers
Aurora, Colorado

Moderator 

Amy Esposito, FNP-C
Nurse Practitioner
Rocky Mountain Cancer Center
Aurora, Colorado

In this episode, Tycel J. Phillips, MD, and Amy Goodrich, RN, MSN, CRNP-AC, provide expert insights on key data presented at ASCO 2022 for mantle cell lymphoma regarding:

• Results from the phase III SHINE study of the addition of ibrutinib the first-line BR followed by rituximab maintenance in older patients with MCL
• Updated results from the phase II ZUMA-2 study evaluating brexucabtagene autoleucel for patients with R/R MCL
• Results from a phase I/II study of the ROR1 humanized monoclonal antibody, zilovertamab, in combination with ibrutinib for patients with R/R MCL, MZL, or CLL/SLL
• Preliminary results from a phase I study of the humanized ROR1xCD3 bispecific antibody, NVG-111, in R/R CLL and MCL after ≥2 previous therapies

Presenters:

Tycel J. Phillips, MD 
Maria Reinhardt Decesare Research Professor of Blood Cancers and Bone Marrow Transplantation
Associate Professor of Medicine
University of Michigan 
Rogel Cancer Center 
Ann Arbor, Michigan

Amy Goodrich, RN, MSN, CRNP-AC
Research Associate, Department of Medicine
Johns Hopkins University
Nurse Practitioner, Department of Medicine
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Content supported by educational grants from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Link to full program, including a downloadable highlights slideset:
https://bit.ly/3yufCU4

In this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current best practices and  emerging strategies in BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with questions including:

• For patients with CLL, when should acalabrutinib-, ibrutinib-, or venetoclax-based regimens be considered?
• What is the optimal therapy for a patient with del(17p) CLL?
• When should an anti-CD20 antibody be added to BTK inhibitor therapy for patients with CLL?
• What are best practices in the use of BTK inhibitors for patients with MCL?
• How can BTK inhibitor resistance occur?
• How might investigational noncovalent BTK inhibitors be used should they be approved?
• What are key adverse events with BTK inhibitors?

Presenters:

Jeff P. Sharman, MD (chair)
Medical Director
Hematology Research
US Oncology 
Willamette Valley Cancer Institute
Eugene, Oregon 

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Anthony Mato, MD, MSCE
Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Content based on an online CME program supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit https://bit.ly/3wXOsV5. 

Link to full program:
https://bit.ly/3NEpsYQ

In this episode, Julie M. Vose, MD, MBA;  Brad S. Kahl, MD; and  John P. Leonard, MD, discuss treatment approaches for patients with B-cell lymphomas, including information on: 

• Follicular lymphoma
• Marginal zone lymphoma
• Mantle cell lymphoma
• Diffuse large B-cell lymphoma
• Posttransplant lymphoproliferative disorder

Presenters:

Julie M. Vose, MD, MBA
Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Brad S. Kahl, MD
Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri

John P. Leonard, MD
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Professor of Medicine
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York

Link to the complete program, including downloadable slidesets, expert commentaries, an on-demand webcast, and treatment resource guides:
https://bit.ly/3tb47wU

In this episode, Keith R. McCrae, MD; Nichola Cooper, MD; and Rachael Grace, MD, MMSc,provide expert insights on immune thrombocytopenia management, along with addressing frequently asked questions from a live CCO symposium. Topics include:

• New and emerging therapeutic options
• Special patient populations, including children
• The management of immune thrombocytopenia
• COVID-19 vaccinations and immune thrombocytopenia

Presenters:

Keith R. McCrae, MD
Professor of Molecular Medicine
Department of Hematology and Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio, USA

Nichola Cooper, MD
Honorary Consultant Hematologist
Hammersmith Hospital
Imperial College
London, United Kingdom

Rachael Grace, MD, MMSc
Associate Professor of Pediatrics
Harvard Medical School
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, Massachusetts, USA

Content based on an online CME program supported by an educational grant from Amgen; Dova Pharmaceuticals, Inc.; and Sanofi Genzyme.

Advances in Immune Thrombocytopenia:
https://bit.ly/3gzykzy

In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing serious adverse events associated with BTK inhibitor therapy. Topics in this podcast include:

• Atrial fibrillation
• Cardiac toxicity
• Musculoskeletal AEs
• Managing risk of infections

Presenter:  

Amy Goodrich, RN, MSN, CRNP-AC  
Research Associate/Nurse Practitioner
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

In this podcast episode, Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this second of 2 podcast episodes on avoiding AEs include:

• Patient adherence to oral medications
• Lifestyle changes
• Monitoring, recording, and reporting of AEs
• The role of the nurse
• The role of the patient
• AE management

Presenter:  

Sandra E. Kurtin, PhD, ANP-C, AOCN
Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona

CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

In this podcast episode,Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this first of 2 podcasts on avoiding AEs include:

• Pharmacokinetics
• Drug metabolism
• Drug–drug interactions
• Drug–food interactions
• The role of CYP enzymes
• Foods to avoid
• Medication review

Presenter:

Sandra E. Kurtin, PhD, ANP-C, AOCN
Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona

CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, provides a nursing-focused overview on available BTK inhibitors in the treatment of CLL and lymphomas. Topics in this podcast include:

• Rationale for inhibiting BTK
• MOA of BTK inhibitors
• Approved BTK inhibitors
• Recent clinical trial findings

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

Presenter: 

Beth Faiman, PhD, MSN, APRN-BC, AOCN
Nurse Practitioner
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing adverse events associated with BTK inhibitor therapy. Topics in this podcast include:

• BTK inhibitor selectivity
• BTK inhibitor adverse event profiles
• Ibrutinib intolerance
• Management of common adverse events

Presenter:

Amy Goodrich, RN, MSN, CRNP-AC
Research Associate/Nurse Practitioner
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub